r2 in the second-line: lenalidomide-rituximab improves pfs in relapsed/refractory nhl
Published 5 years ago • 200 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
2:05
augment-ing treatment: lenalidomide plus rituximab for r/r indolent nhl
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
4:47
ash 2014: phase ii/iii study of lenalidomide in relapsed/refractory diffuse large b-cell lymphoma
-
4:58
choosing second-line therapy for relapsed/refractory fl
-
0:58
improving second-line treatments in dlbcl
-
4:23
second-line treatment options for rcc
-
0:43
overview of r2 regimen for relapsed follicular lymphoma
-
0:59
dr. lee on second-line treatment options in rcc
-
2:07
addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
-
2:23
re-mind2: observational study comparing tafasitamab lenalidomide to available therapies in r/r dlbcl
-
5:24
second-line treatment for recurrent or progressive gec
-
0:45
majestec-2 update: teclistamab plus lenalidomide in r/r multiple myeloma
-
1:22
safety and efficacy of golcadomide (cc-99282) in the treatment of r/r nhl
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
1:10
fl - highlights on r2 (rituximab lenalidomide)
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:46
transform: liso-cel versus standard of care as second-line therapy for r/r lbcl
-
2:37
potential second-line treatment for indolent lymphoma